Adverse events in the paediatric emergency department: a prospective cohort study

Amy C Plint1,2, Antonia Stang3,4, Amanda S Newton5,6

  • 1CHEO, Ottawa, Ontario, Canada plint@cheo.on.ca.

Insights

Approximately 2.5% of children treated in the emergency department (ED) experienced adverse events, with most being preventable. Further research into management and diagnostic issues is recommended for improving pediatric patient safety.

Area of Science:

  • Pediatric Emergency Medicine
  • Patient Safety Research
  • Healthcare Quality Improvement

Background:

  • Adverse events in pediatric emergency departments (EDs) present opportunities to enhance patient safety.
  • Resource limitations necessitate focused efforts on high-impact areas for safety improvements.

Purpose of the Study:

  • To quantify the risk, types, preventability, and severity of adverse events in children treated in a pediatric ED.
  • To identify specific areas for intervention to improve pediatric patient safety.

Main Methods:

  • A prospective cohort study involving 1367 children over one year in a pediatric ED.
  • Telephone interviews and health record review using a validated trigger tool identified potential adverse events.
  • Independent physician review confirmed adverse events and assessed preventability and severity.

Main Results:

  • 2.5% of children experienced an adverse event related to ED care within three weeks of their visit.
  • The majority of adverse events (87.9%) were deemed preventable.
  • Common adverse events included management issues (51.5%), diagnostic issues (45.5%), and suboptimal follow-up (15.2%).

Conclusions:

  • One in 40 children encountered adverse events linked to emergency department care.
  • A significant proportion of these events were preventable, highlighting areas for targeted interventions.
  • Management and diagnostic issues are key areas requiring further investigation to reduce pediatric adverse events.
Abstract

Related Concept Videos

Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.5K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
148
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
194
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
170
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
190
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
130